A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking Cessation

Completed · Phase 2

Conditions studied: Smoking Cessation

In brief

The purpose of the study is to measure the safety and efficacy of three doses of varenicline for smoking cessation.

Key facts

Study ID

NCT00150241

Run by

Pfizer

People needed

625

Starts

2000-02-01

Expected to finish

2002-01-01

Last updated by the study team

2015-10-19

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must have smoked on average of at least ten cigarettes per day during the past year
• Subjects must have no period of abstinence greater than three months in the past year

You may not qualify if…

• Subjects with any history of cardiovascular disease
• Myocardial infarction
• Significant arrhythmias
• Poorly controlled hypertension

Where it is running

• Pfizer Investigational Site — Los Angeles, California, United States
• Pfizer Investigational Site — Farmington, Connecticut, United States
• Pfizer Investigational Site — Minneapolis, Minnesota, United States
• Pfizer Investigational Site — Omaha, Nebraska, United States
• Pfizer Investigational Site — New York, New York, United States
• Pfizer Investigational Site — Portland, Oregon, United States
• Pfizer Investigational Site — Morgantown, West Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.